Oral squamous cell carcinoma (OSCC) ranks among the top 8 causes of cancer death worldwide, with only a 60% 5-year survival rate, highlighting the need for discovery of novel biomarkers and therapeutic targets. We have previously reported that expression of a panel of serine proteinase kallikreins (KLK 5, 7, 8, and 10) is correlated with formation of more aggressive OSCC tumors in a murine orthotopic OSCC model and is elevated in human OSCC. Current studies focus on understanding the potential role of KLK5 in OSCC progression. In initial studies, KLK levels in malignant OSCC cells (SCC25) were compared with cells from normal oral mucosa (OKF/6) and pre-malignant oral keratinocytes (pp126) using qPCR. A marked elevation of all KLKs was observed in aggressive SCC25 cells relative to OKF/6 cells. In normal skin, KLKs are involved in desquamation during epidermal differentiation via proteolytic cleavage of the desmosomal cadherin component desmoglein 1 (Dsg1). As loss of cell-cell cohesion is prevalent in tumor metastasis, Dsg1 integrity was evaluated. Results show that SCC25 cells exhibit cleavage of Dsg1, which is blocked by proteinase inhibitor treatment as well as by siRNA silencing of KLK5 expression. Furthermore, cell-cell aggregation assays demonstrate that silencing of KLK5 enforces cellcell adhesion; conversely, overexpression of KLK5 in normal oral mucosal cells (OKF/6) enhances cell dispersal. These data suggest that KLK5 may promote metastatic dissemination of OSCC by promoting loss of junctional integrity through cleavage of desmoglein 1.Oral cavity cancer results in over 200,000 deaths annually and is one of the top eight most frequently diagnosed cancers worldwide (1). The most common malignancy of the oral cavity is oral squamous cell carcinoma (OSCC), 3 including tumors affecting the tongue, floor of the mouth, buccal mucosa, lips, palate, and gingiva, causing more deaths than any other oral disease (2-3). According to National Cancer Institute statistics, about 23,110 new cases of oral cancer were diagnosed in 2009 in the United States (4). Unfortunately, despite advancements in surgery, chemotherapy, and radiation, only 60% of these individuals will survive for five years. The high mortality associated with OSCC is due primarily to the detection of late-stage disease after the primary tumor has metastasized. Treatment of advanced OSCC is also associated with high morbidity and mortality, resulting from local, regional, and distant metastasis (2-3). The cellular and biochemical factors that underlie locoregional and distant spread of the disease are poorly understood. Invasion and metastasis of OSCC require multiple cellular events including disruption of cell-cell adhesive contacts, cytoskeletal alterations, and basement membrane attachment, matrix protein proteolysis, and migration (5-6). Thus a more detailed analysis of the molecular events that contribute to OSCC metastasis is a necessary prerequisite for the development of novel early detection and treatment strategies that have a favorable im...